Clinical Trial Update: A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan

View source ↗

Summary

A clinical trial in Japan is evaluating the effectiveness and safety of first-line nivolumab plus ipilimumab, with or without chemotherapy, for advanced or recu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer | Status: ACTIVE_NOT_RECRUITING